Cardiol Therapeutics Inc (CRDL) Stock Overview, News & Analysis

Company Overview

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

Contact Details

Address: 2265 UPPER MIDDLE ROAD EAST SUITE 602
City: OAKVILLE
State: A6
Country: CAN
Zip Code: L6H 0G5
Phone Number: 289-910-0850
Website: https://www.cardiolrx.com/

Financial Highlights

Day Range The price range a stock has traded at during the most recent trading period.: -

-
5 Day Range The price range a stock has traded at during the previous 5 days.: -

-
3 Month Range The price range a stock has traded at during the previous 3 months.: -

-
52 Week Range The price range a stock has traded at during the previous 52 weeks.: -

-
Previous Close The closing price of a stock from the previous day.: -
Open The price of the stock at the start of today’s market opening.: -
Bid The amount of money a trader is willing to pay per share for a given stock.: x
-
Ask The amount of money a seller wants per share of a given stock.: x
-
Volume The number of shares traded in a given period. This number illustrates the active interest in the stock at any time.: -
Avg. Volume The average number of shares traded in a given day.: -
Dividend Yield A company's annual dividend expressed as a percentage of its current stock price.: -
Recent Dividend The value a shareholder receives from a company they are invested in for holding their shares.: -
Beta A measurement of the stock’s volatility in comparison to the market as a whole.: -

Shareholding

Shares Outstanding Number of shares currently held by investors, including restricted shares owned by the company's officers and insiders.: -
Insider Shareholders The percentage of shares owned by any officer or board director of the company, including their related or affiliated individuals, families, entities and trusts.: -
Institutional Shareholders The percentage of shares owned by an institution such as a mutual fund, bank or insurance company.: -

Market Cap The market value of a company’s outstanding shares. It is used as a measurement tool to determine how large a company is.: -
Revenue TTM The amount of money a company has made for the trailing twelve-month period.: -
Net Income TTM A measurement of how much profit they are retaining for the trailing twelve-month period.: -
P/E Ratio The Price to Earnings (P/E) ratio, is calculated by dividing the stock's most recent share price by the sum of the diluted earnings per share.: -
EPS TTM Earnings Per Share (EPS) TTM is a company's profit for the trailing twelve-month period divided by its number of common outstanding shares.: -
1 Year Return A measurement of how much the stock has increased or decreased in the last year.: -

There is no stock data currently available for this time period, please select another option.

Please wait, gathering market data...

Management Team

Cardiol’s comprehensive team has all the bases covered. It includes exceptional management, an impressive and independent Board of Directors, and renowned Scientific and Business Advisors.

David Elsley, MBA

President and CEO

In 1990, Mr. Elsley founded Vasogen Inc., a biotech company developing novel therapeutics to treat heart failure and other inflammatory conditions. Mr. Elsley managed Vasogen’s growth and established the R&D infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies to pivotal Phase III clinical trials involving 2,500 patients.

Dr. Guillermo Torre-Aminone, MD, PhD

Chairman

Dr. Torre-Amione serves as Cardiol’s Chair of the Board. He is an esteemed gentleman with highly impressive credentials and experience. Board-certified in cardiovascular disease and Advanced Heart Failure/Transplant Cardiology, Dr. Guillermo Torre-Amione is Professor of Cardiology at The Methodist Hospital Research Institute, Houston, Professor of Medicine at the Weill Cornell Medical College of Cornell University, New York, and President of TecSalud, an academic medical center and medical school in Mexico.

Jennifer M. Chao, BA

Director

The most recently appointed Board member and Wall Street veteran, Ms. Chao, has over 25 years of experience in the biotech and life sciences, focusing primarily on finance and corporate strategy.

Colin G. Stott, BSc (Hons)

Director

Mr. Stott is a world-leading pharmacologist in cannabidiol treatments. He is a former Director for GW Pharma and veteran of the pharmaceutical and biotech industries, having almost 30 years of experience in pre-clinical and clinical development.